Abeona Therapeutics Inc. - Special Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Congrats on these data updates. So the first question I had is whether you saw any further benefits on the secondary outcome biomarker measures, specifically in cohort 3 when looking at the younger patients? So in other words, how correlated do you believe that all of these endpoints are?

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Can you hear me better now?

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Yes. Sorry about that. So the question was just on whether you saw any further benefits on the secondary outcome biomarker measures, specifically with the younger patients? I know -- you noted that there is a dose-escalating response. But how about, again, for these younger patients that seem to be doing much better? And then how correlated do you believe these endpoints are? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

Question: Kristen Brianne Kluska - Cantor Fitzgerald & Co., Research Division - Analyst : Got it. And then my second question here is given the evidence from both Abeona and other companies in the gene therapy space, that early intervention may lead to more robust benefits. What work do you anticipate needs to be done in the MPS III landscape to ensure that patients are getting diagnosed at an earlier age?